AFP and neoplasm: Comparing sensitivities for methylated genes vs. methylated genes plus tumor-specific protein markers (CEA, AFP, CA19-9), an increase was observed (from 35.3 to 47.1% for stage 0+I, 48.6 to 74.3% for stage II, 64.0 to 80% for stage III, and 89.7 to 96.6% for stage IV) [51].